ADVERSE DRUG REACTIONS IN PEDIATRIC PATIENTS IN A TERTIARY CARE HOSPITAL IN KOLLAM
Objective: Adverse drug reactions have not been as thoroughly studied in children as they have in adults. Extrapolation of efficacy, dosing regimens, and ADRs from adult data are inappropriate owing to developmental changes in physiology and drug handling. There is a lack of local data regarding the potential risk of ADRs in pediatric patients. Objective of this study is to identify the adverse drug reaction (ADR) profile in pediatric patients.
Methods: In this cross-sectional study, 450 children attending the pediatric inpatient and outpatient department were selected, and the CDSCO reporting form for suspected ADR reporting forms was collected from those who had any adverse events by the consulting pediatrician. Later, this form was analyzed for the details for ADRs and assessed for causality, severity, and preventability using Naranjo’s algorithm, Hartwig and Siegel scale, and modified Schumock and Thornton scale of adverse drug reactions.
Results: The cross-sectional study revealed a prevalence of 12.89%. Antibiotics caused more ADRs than any other group of drugs. Dermatological ADRs were the most common. Most ADRs were not preventable and were of moderate severity. The causality assessment showed that most ADRs were possible category.
Conclusion: The ADRs are often unrecognized. We need more strict monitoring for early detection, treatment, and more importantly prevention of these events in the future. For that, more awareness programs, CMEs and teamwork are extremely important among the caregivers.
2. Kearns GL, Abdel-Rahman S, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67.
3. Naranjo CA, Busto U, Sellers P, Ruiz I, Roberts EA, Janecek E, Domecq C, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
4. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
5. Schumock GT, Thornton J. Focusing on the Preventability of adverse drug reactions. Hosp Pharm 1992;27:538.
6. Mandha M, Reddy KP, Reddy KR. Evaluation of adverse drug reactions in pediatric patients. Indian J Pharm Pract 2013;6:32-5.
7. Clavenna A, Bonati M. Adverse drug reactions in childhood: A review of prospective studies and safety alerts. Arch Dis Child 2009;94:724-8.
8. Priyadharsini R, Surendiran A, Adithan C. A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother 2011;2:277-80.
9. Khan LM, Al-Harthi SE, Saadah OI. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J 2013;21:261-6.
10. Shamim M, Ali MD, Alam MS, Ali MS, Ahmad S, Ansari MS. Drug utilization based adrs detection of antibiotics prescribed for LRTI in tertiary care teaching hospital, New Delhi. Int J Pharm Pharm Sci 2018;10:7-14.
11. Napoleone E. Medicines for children ADRs: From spontaneous reporting to active surveillance. Child Care Health Dev 2009;36:106-7.
12. Digra KK, Pandita A, Salini GS, Bharti R. Pattern of adverse drug reactions in children attending the department of pediatrics in a tertiary care center: A prospective observational study. Clin Med Insights Ped 2015;9:73-8.
13. Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse drug reactions in children-a systematic review. PLoS One 2012;3:e24061.
14. Kumar L. Pharmacovigilance/reporting adverse drug reactions: An approach to enhance health surveillance and extending market share by minimizing the chances of drug withdrawals. Int J Pharm Pharm Sci 2015;7:1-7.
15. Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety: Need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol 2011;18:e76-88.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.